Categories Uncategorized

Study Finds Psilocybin Users Less Inclined to Work Overtime

“Quiet quitting” is a phenomenon where employees put in the minimum effort, time and enthusiasm required of them at their jobs and don’t go out of their way to create any extra value for their employers. The trend has picked up a lot of steam in recent years as employees have begun prioritizing a strict work-life balance and finding value in their hobbies and other experiences rather than work.

Increased employee demands and stagnating wages coupled with increasing living costs have made many employees question if going the extra mile, whether it’s through arriving early, taking part in nonmandatory meetings or leaving late, adds any value to their lives.

Recent research now reveals that there may be a correlation between psilocybin or magic mushroom use and reduced overtime hours in psychedelic users who work full time. University of Bamberg postdoctoral researcher and study author Benjamin A. Korman says he was motivated to carry out the study due to the growing body of research on the therapeutic efficacy of psychedelics, increasing rates of quiet quitting and reports that employees are using more psychedelics.

He analyzed National Survey and Drug Use and Health (NSDUH) data collected from more than 217,000 fully employed individuals aged 18 and older between 2002 and 2014. The researchers found a positive association between psychedelics and less overtime worked, with individuals who had used psilocybin at least once in their lives working fewer overtime hours compared to nonpsilocybin users.

Psilocybin is part of a psychedelic research renaissance that has connected various psychedelics with major reductions in the symptoms of mental disorders including anxiety, depression and post-traumatic stress disorder (PTSD). Research has also found that psychedelics can cause profound changes in how people perceive themselves and the world at large, allowing them to recontextualize previous experiences and move forward from traumas that were holding them back.

Although prior research has done little to explore how psychedelic use can affect day-to-day life, the recent study indicates that psilocybin use may encourage full-time workers to prioritize their work-life balance and refrain from putting any extra effort into their work. Rather than going over and above by either taking on extra work, being proactive in meetings or spending as much time at the office, individuals are prioritizing their mental health, relationships, and personal well-being.

While this shift is undoubtedly beneficial for typically stressed and overworked employees, it is sending waves of panic through board rooms and the C-suite.

As companies such as Compass Pathways PLC (NASDAQ: CMPS) conduct further studies on these psychedelic substances, much more is likely to come to light regarding the beneficial effects that can arise when people use controlled doses of hallucinogens.

About PsychedelicNewsWire

PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

PsychedelicNewsWire
San Francisco, CA
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicNewsWire.com

PsychedelicNewsWire is powered by IBN

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 months ago